Gain and loss of *cis*-regulatory elements (CREs) alter gene regulatory networks and as a consequence can result in morphological variation and sometimes genetic disease ([@r1], [@r2]). Changes in CRE function have restricted effects on specific tissues or organs, whereas mutations in protein-coding sequences can affect multiple tissues and organs where the mutated gene is expressed and often result in drastic phenotypes including embryonic lethality. The restricted effect mentioned above is probably relevant to the fact that functional changes in CREs have contributed to evolution more often than coding sequence mutations ([@r3], [@r4]).

To date, studies of genome variations that cause morphological alteration and disease have focused on coding sequences, which comprise around 1.5% of the whole genome. By contrast, studies of functional change in CREs, which is responsible for phenotype alteration, have been hampered by the fact that sequences of CREs are less well annotated than the coding sequences and because the molecular basis underlying change in CRE function is still poorly understood. In particular, little attention has been paid to structural variations, including insertion, deletion, inversion, and translocation, as a driving force for change in gene regulation. The only exception is the study of transposable elements (TEs): There are many lines of evidence that insertion of a TE harboring enhancer activity into an unrelated genomic region gives rise to a novel expression pattern for the gene neighboring the insertion ([@r5], [@r6]). Some genomic structural variations may reconfigure the connection between CREs and their target coding sequences on the chromosome ([@r7]). Recent advances in sequencing technology have revealed a number of structural variants from 100 bp to 1 Mbp in length in human genomes. However, there are very few reports that such variants are associated with a change in gene regulation that leads to morphological change and disease ([@r8], [@r9]).

In this study, we present an example of the acquisition of a novel expression pattern for a developmental gene as a result of structural rearrangement in the genome. Hammer toe (*Hm*) is an old spontaneous mouse mutant that exhibits soft tissue syndactyly associated with interdigital webbing ([@r10]), which is caused by a reduction of interdigital cell death ([@r11]). Previous genetic linkage analyses mapped the *Hm* locus to the region upstream of Sonic hedgehog (*Shh*). In the developing limb bud, *Shh* is expressed in a cell population named the zone of polarizing activity (ZPA) in the posterior mesenchyme, and *Shh* signaling is crucial for anterior--posterior (AP) patterning and determination of digit identity ([@r12]). *Shh* expression in the ZPA is regulated by a limb bud-specific enhancer named MFCS1 (also known as ZRS), which is located 840 kb upstream of the *Shh* promoter ([@r13][@r14]--[@r15]). Many mutations in the MFCS1 sequence are known to cause preaxial polydactyly, but not syndactyly, in both human and mouse ([@r16], [@r17]).

We extended the linkage analysis and exploration of structural variation in the *Hm* genome and found that a chromosome 14 (Chr14)-derived 150-kb noncoding DNA fragment is inserted into the interval between the *Shh* promoter and MFCS1 in the *Hm* genome and that it elicits ectopic *Shh* expression in the interdigital region of the developing limb. The ectopic *Shh* expression in turn down-regulates bone morphogenetic protein (BMP) signaling, leading to a reduction of interdigital cell death and finally resulting in the syndactyly and interdigital webbing phenotype. Thus, we provide unequivocal evidence that interchromosomal translocation is able to generate enhancer activity for a developmental gene, which ultimately leads to morphological alteration.

Results {#s1}
=======

*Hm* was reported to be tightly linked to another old mutation named Hemimelic extra toe (*Hx*) that causes hemimelia and preaxial polydactyly. Only one recombinant was detected between *Hx* and *Hm* in a previous study ([@r18]). Since a single nucleotide substitution was identified in MFCS1 as the causative mutation of *Hx* ([@r13], [@r14]), we first sequenced MFCS1 from the *Hm* genome. The result did not show any kind of mutation in MFCS1.

A subsequent linkage study narrowed the critical region of *Hm* to a 420-kb interval between two DNA markers, D5kng2 and D5kng3 ([@r19]) ([Fig. 1*A*](#fig01){ref-type="fig"}). We extended the linkage analysis based on intercrosses of the *Hm* heterozygotes (*Hm/+*) that were generated from crosses of *Hm/+* and each of three inbred strains---KJR/Ms, BLG/Ms, and MSM/Ms---established from highly polymorphic wild mice ([@r20]) and also a backcross involving a *Shh*-coding knockout (KO) mouse ([Fig. 1*B*](#fig01){ref-type="fig"}). In total, we obtained 12 recombinants from these crosses and thereby assigned the DNA marker NIG6 to the most distal border and NIG2 to the most proximal border of the *Hm* region ([Fig. 1*B*](#fig01){ref-type="fig"}). This result confined the *Hm* region to the segment depicted by the green bar in [Fig. 1*A*](#fig01){ref-type="fig"}. By combining the results of the former linkage analysis ([@r19]) with these, we further confined *Hm* to a 270-kb interval between D5kng2 and NIG6 ([Fig. 1*A*](#fig01){ref-type="fig"}).

![Linkage analysis of the *Hm* mutation. (*A*) Genetic map around the *Shh* locus in mouse Chr5. Vertical black and green bars indicate the *Hm* region defined by Clark et al. ([@r19]) and the present study, respectively. The vertical magenta bar depicts the deleted 80 kb. DNA markers are shown on the left side of the map. (*B*) Haplotype panel of backcrosses. Microsatellite and DNA marker loci used are listed to the left side of the panel. The number of progeny with each haplotype is listed at the bottom of each haplotype column. Solid squares represent the *Hm* allele, and open squares represent the alleles of KJR, MSM, BGL, and *Shh* KO. The mating pairs and the numbers of meioses observed in each backcross are shown below the haplotype panel. (*C*) Mating scheme and the resultant recombinants between *Hm* and the *Shh* coding KO chromosomes. Phenotype and numbers of each recombinant are shown at the bottom. (*D*) Mating scheme and the revertant recombinants between *cis*1 and wild-type B6 chromosomes. Phenotype and number of revertants are shown at the bottom. (*E*) Genotype of two recombinants. *Hm*, B6, and *Shh* coding KO on the genetic background of strain 129/SV around the *Shh* locus are represented by *Hm*, B6, and 129-KO, respectively.](pnas.1713339115fig01){#fig01}

Because *Hm* is tightly linked to the *Shh* locus, we examined whether *Hm* acts in *cis* on *Shh*. From the same backcross progeny used in the linkage analysis, we obtained four recombinants between the *Shh*-coding KO allele and the DNA marker NIG2 ([Fig. 1*C*](#fig01){ref-type="fig"}). Two of these, referred to as *cis*1/B6 and *cis*2/B6, have a recombinant chromosome carrying the *Hm* region and the *Shh*-coding KO allele. They exhibited normal limb phenotype, indicating a *cis*-acting nature for *Hm*. This was confirmed by the finding that genetic restoration of the *Shh* coding sequence in the *cis*1 recombinant chromosome yielded the syndactyly phenotype ([Fig. 1 *D* and *E*](#fig01){ref-type="fig"}). Thus, this *cis--trans* test showed unequivocally that the regulation by *Hm* acts in *cis* on *Shh*.

Because the syndactyly of *Hm* is a dominant phenotype and is likely caused by the gain of a new regulatory activity, we anticipated that removing the mutated region from the *Hm* genome could rescue its phenotype. Because two *Shh* enhancers, MFCS4 and MACS1, which are necessary for postnatal viability, are located in the distal side of the 270-kb *Hm* region between NIG4 and NIG6 ([@r21], [@r22]), we first removed 80 kb that does not contain the two enhancers ([Fig. 1*A*](#fig01){ref-type="fig"}, magenta bar). Mice with the deletion showed normal digits, indistinguishable from those of wild-type mice ([Fig. 2 *A*--*D*](#fig02){ref-type="fig"}). This result indicated that the causative mutation is contained within the 80 kb on the reference mouse genome (GRCm38/mm10), which does not contain any coding sequence ([Fig. 1*A*](#fig01){ref-type="fig"}).

![Genomic insertion caused the *Hm* mutation. (*A*--*E*) Micro-CT images of right hind limb from (*A*) wild-type, (*B*) Hm/+, (*C*) *Hm/Hm*, (*D*) *HmΔ80/+*, and (*E*) *HmΔHIS/+* at P0 (day of birth). (Scale bars, 1 mm.) (*F*) PCR-amplified DNA fragments from wild-type (WT) and *Hm* genomes. Green and magenta arrows indicate primer pairs for the amplifications shown in *G*. Leftmost lane is λ-HindIII as DNA marker. (*G*) Schematic diagram of genomic insertion of a fragment derived from Chr14 into Chr5 in the *Hm* mutation. The original sequence of HIS in Chr14 is marked by a black bar (Chr14: 110087232--110237755, GRCm38). Green and magenta indicate primers used for PCR with genomic DNAs of WT and *Hm* mice. Arrowheads indicate target positions of the CRISPR/Cas9 system, used to induce the ΔHIS modification. (*H*) *LacZ* expression in a BAC transgenic mouse with *RP23-444D12-LacZ* at E13.5. (*I*) Ventral view of *LacZ* expression in the left forelimb of the BAC transgenic mouse in *H*. Arrowheads indicate *LacZ* expression in interdigital regions. (*J*) ATAC-sequencing in the 150 kb of original HIS region in chr14 from the *Hm* homozygote (upper track) and wild-type mouse (lower track). Gray bars indicate regions 1 and 2. Magenta bars indicate seven called peaks in HIS. (*K*--*O*) Ventral view of *LacZ* expression in the left forelimb of a transgenic mouse with *e2-LacZ* (*K*) (*n* = 3/12), *e3-LacZ* (*L*) (*n* = 0/6), *e5-LacZ* (*M* and *N*) (*n* = 5/6), *e6-LacZ* (*O*) (*n* = 0/7), and *e7-LacZ* (*P*) (*n* = 1/8) at E13.5. Each *n* indicates the number of LacZ expression in autopod per transgenic mouse.](pnas.1713339115fig02){#fig02}

Next, to explore the genomic variation responsible for *Hm* in this 80 kb, we amplified genomic fragments using tiling PCR primer pairs from *Hm*-homozygous and wild-type mice ([Fig. S1*A*](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1713339115/-/DCSupplemental)). We found that no fragment was amplified with the primer pair F specifically from the *Hm* genome, suggesting a structural variation in a long interspersed nuclear element (LINE) sequence that resides in the 80 kb. Subsequent inverse PCR identified the structural variation in this LINE sequence ([Fig. S1*B*](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1713339115/-/DCSupplemental)). Sequencing revealed that the fragment amplified by the inverse PCR contains abnormal junctions of Chr5 and Chr14 ([Fig. S1*C*](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1713339115/-/DCSupplemental)). We confirmed the presence of these junctions by genomic PCR ([Fig. 2*F*](#fig02){ref-type="fig"}). These results indicated that a 150-kb fragment residing in the intergenic region between *Slitrk1* and *Slitrk6* in Chr14 is inserted into the region upstream of *Shh* in Chr5 ([Fig. 2*G*](#fig02){ref-type="fig"}). No coding sequences or noncoding RNAs are annotated in this 150-kb fragment. We termed this fragment the *Hm* inserted sequence (abbreviated as HIS).

To determine whether the HIS insertion directly causes the syndactyly phenotype of *Hm*, we removed the LINE sequence containing HIS from the *Hm* genome using the CRISPR/Cas9 system ([Fig. 2*G*](#fig02){ref-type="fig"} and [Dataset S2](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1713339115/-/DCSupplemental)). A mouse line with this deletion showed normal digits that were indistinguishable from those of wild-type mice ([Fig. 2*E*](#fig02){ref-type="fig"}). The homozygote of the HIS-deleted *Hm* mutant was viable and did not show any abnormal phenotype in the whole limb or in other organs. This result indicated that the original LINE sequence in the *Hm* region in Chr5 has no significant function in mouse development. Thus, we conclude that insertion of HIS was the direct cause of *Hm*.

To test whether the original HIS in the normal mouse Chr14 has enhancer activity, we performed a transgenic reporter assay using BAC clone RP23-444D12, which was isolated from the B6 genome library and harbors the HIS in Chr14 ([Fig. 2*G*](#fig02){ref-type="fig"}). We made a transgene construct, introducing a *LacZ* reporter gene into the BAC clone. Transgenic mouse embryos with this construct showed reporter expression in the interdigital region at E13.5 ([Fig. 2 *H* and *I*](#fig02){ref-type="fig"}). The LacZ signals were more abundant on the ventral side than on the dorsal side. This difference in signal intensity along the dorsoventral axis correlates well with the fact that interdigital cell death in the *Hm* limb is more severe on the dorsal side than on the ventral side ([@r11]). Therefore, HIS in Chr14 of strain B6 appears to possess enhancer activity to elicit gene expression in the interdigital regions of mouse limbs.

To assess the function of the original HIS in wild type, we removed HIS from Chr14 using the CRISPR/Cas9 system. Mice homozygous for the deletion did not show any developmental abnormality, including limb phenotype ([Dataset S2](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1713339115/-/DCSupplemental)), suggesting no significant role for HIS in Chr14 in morphogenesis.

To find regulatory region(s) of HIS, we generated a series of partial deletion of HIS in the *Hm* genome by the CRISPR/Cas9 system ([Fig. S2](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1713339115/-/DCSupplemental)). Observation of the phenotype of these deletion mutants indicated that the middle part of HIS (region 1) was necessary to cause the syndactyly phenotype of *Hm*. Moreover, another part of HIS (region 2), which resides at the *Shh* side and shares no sequence similarity with region 1, was also required for syndactyly.

Next, to identify enhancers in HIS, we searched open chromatin regions by using ATAC-sequencing (ATAC-seq) with distal autopod cells from E13.5 embryos. We found seven peaks in the 150 kb of HIS (magenta bars of e1 to e7 in [Fig. 2*J*](#fig02){ref-type="fig"}). Among them, two peaks (e1 and e4) were not included in regions 1 and 2. We carried out transgenic reporter assays with the five peaks excluding e1 and e4 by inserting each fragment upstream of the hsp promoter and *LacZ* sequence ([Dataset S3](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1713339115/-/DCSupplemental)). Out of the five peaks to be tested, we found three autopod enhancers ([Fig. 2 *K*--*P*](#fig02){ref-type="fig"}). The e2 peak induced interdigital expression of *LacZ* ([Fig. 2*K*](#fig02){ref-type="fig"}). The e5 peak directed the expression of *LacZ* mainly in digits sometimes with a broad signal in the entire autopod, including interdigit regions ([Fig. 2 *M* and *N*](#fig02){ref-type="fig"}). The e7 peak induced interdigital expression of LacZ, although the signal was observed in only one embryo ([Fig. 2*P*](#fig02){ref-type="fig"}). The other two peaks induced no LacZ signals in the limb ([Fig. 2 *L* and *O*](#fig02){ref-type="fig"}).

In the CRISPR/Cas9-mediated deletion experiment of HIS, we obtained G0 mice with a more severe syndactyly phenotype than that in the original *Hm* heterozygote. Sequencing of PCR products amplified from the *Hm* genome with a primer pair for the 3′ junction indicated that a CRISPR/Cas9-mediated inversion of HIS had occurred in the G0 mouse ([Fig. 3*A*](#fig03){ref-type="fig"} and [Dataset S2](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1713339115/-/DCSupplemental)). We named this HIS inverted allele *Hm-inv* and found that mice heterozygous for *Hm*-*inv* showed neonatal lethality; in contrast, both heterozygotes and homozygotes of the original *Hm* are fully viable. The *Hm*-*inv* heterozygotes exhibited swollen soles and a cleft palate, which were not observed in the original *Hm* heterozygotes ([Fig. 3*B*](#fig03){ref-type="fig"}). Sagittal and transverse sections of X-ray micro-computed tomography (micro-CT) images showed that the volume of muscle fiber in the *Hm*-*inv* heterozygotes was increased in the swollen sole ([Fig. 3 *D*--*I*](#fig03){ref-type="fig"}). On the other hand, each phalange was normal ([Fig. 3 *D*--*I*](#fig03){ref-type="fig"}).

![Regulatory activity of HIS depends on its orientation. (*A*) Schematic diagram of inversion of HIS by the CRISPR/Cas9 system. Arrowheads indicate target sites and are identical to the arrowheads in *G*. (*B* and *C*) Micro-CT images of right hindlimb of (*B*) *Hm/+* and (*C*) *Hm-inv/+* mice at P0. (Scale bars, 1 mm.) The image in *B* is identical to that of [Fig. 2*B*](#fig02){ref-type="fig"}. (*D*--*F*) Sagittal sections of micro-CT images of right hindlimb of (*D*) wild type, (*E*) *Hm/+*, and (*F*) *Hm-inv/+*. The red arrowhead in *F* indicates increased muscle fiber. (*G*--*I*) Transverse sections of micro-CT images at the positions shown by the yellow dotted bars in *D*--*F*.](pnas.1713339115fig03){#fig03}

We examined the interaction between *Hm* and MFCS1, because MFCS1 is a sole enhancer necessary and sufficient for *Shh* expression in normal limb development ([@r21]). We eliminated MFCS1 from the *Hm* genome using the CRISPR/Cas9 system ([Fig. S3*A*](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1713339115/-/DCSupplemental)). Among the G0 pups generated, two individuals exhibited truncated limbs, resembling the phenotype of the MFCS1 KO mouse, indicating that MFCS1 was successfully eliminated from both chromosomes in these two pups ([Fig. S3*B*](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1713339115/-/DCSupplemental)). We then crossed the G0 male to B6 and established a mouse line in which the MFCS1-eliminated chromosome (*ΔMFCS1*) is located at the *cis*-position relative to *Hm*. All mice of this line (*Hm*, *ΔMFCS1/+*) clearly exhibited syndactyly, similar to the original *Hm* heterozygotes ([Fig. S3*C*](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1713339115/-/DCSupplemental)). Therefore, the presence of MFCS1 in *cis* relative to *Hm* is not necessary to generate the syndactyly phenotype of *Hm*. In other words, the limb enhancer MFCS1 is dispensable for *Hm* action.

To determine the effect of HIS on *Shh* regulation, we analyzed the expression level of *Shh* mRNA, using qRT-PCR, in the *Hm* mutant limb at different stages from E11.5 to E15.5. We first examined *Shh* expression at the early embryonic stage (E11.5), when *Shh* expression remains in the ZPA. Expression was observed in both the *Hm* homozygote and the wild-type embryo, but its level was 2.6-fold higher in the *Hm* homozygote ([Fig. 4*A*](#fig04){ref-type="fig"}). After *Shh* expression ceases in the ZPA, interdigital cell death proceeds from E12.5 to E15.5. During these later stages, significantly higher *Shh* expression was observed in the *Hm* limb than in the wild-type limb ([Fig. 4*B*](#fig04){ref-type="fig"}).

![Ectopic *Shh* expression in *Hm*. (*A*--*D*) Expression level of *Shh* in the autopod was measured by qRT-PCR. Expression level was normalized as 1/1,000 of the value for *Actb*. (*A*) E11.5 limb bud, *n* = 8; (*B*) E12.5 and E15.5 autopod, *n* = 8; (*C*) E13.5 autopod, *n* = 8 for each genotype; and (*D*) E13.5 interdigital region, *n* = 3. (*E* and *F*) Ventral views of in situ hybridization of *Shh* in E13.5 forelimb of wild-type (*E*) and *Hm-inv/+* (*F*) mice. The yellow arrowhead in *F* indicates interdigital expression of *Shh*. (*G* and *H*) In situ hybridization of *Shh* in E11.5 hind limb of wild-type (*G*) and *Hm/Hm* (*H*) mice. \**P* \< 0.05, \*\**P* \< 0.001, \*\*\**P* \< 0.0001 in Welch's *t* test.](pnas.1713339115fig04){#fig04}

We examined the dose effect of the *Shh* expression level on phenotypic severity at E13.5. We found that the expression level correlated well with dose of the *Hm* allele, and the *Hm*-*inv* allele showed an extremely high level of *Shh* expression ([Fig. 4*C*](#fig04){ref-type="fig"}). When HIS was removed from Chr5, the heterozygote (*HmΔHIS/+*) did not show ectopic expression of *Shh*. Thus, the level of ectopic *Shh* expression correlated with the severity of syndactyly.

Next, we analyzed the localization of ectopic *Shh* expression in the autopod. RT-PCR of mRNA prepared from the interdigital region at E13.5 showed ectopic expression of *Shh* in the *Hm* homozygote but not in the wild-type embryo ([Fig. 4*D*](#fig04){ref-type="fig"}). This ectopic *Shh* expression was not detected by in situ hybridization in the *Hm* homozygote, probably due to its lower expression level. On the other hand, in situ hybridization of the *Hm*-*inv/+* embryo clearly showed ectopic *Shh* expression in the interdigital region ([Fig. 4 *E* and *F*](#fig04){ref-type="fig"}, yellow arrowhead), reflecting the high level of *Shh* mRNA ([Fig. 4*C*](#fig04){ref-type="fig"}). *Shh* expression was more abundant on the ventral side than the dorsal side, consistent with the *LacZ* expression pattern of the BAC transgenic mouse ([Fig. 2*I*](#fig02){ref-type="fig"}), as well as with the biased interdigital cell death along the dorsoventral axis.

There was no obvious difference in the *Shh* expression pattern in the limb bud between the *Hm* homozygote and wild-type embryo at the early stage of limb development (E11.5) ([Fig. 4 *G* and *H*](#fig04){ref-type="fig"}). This result is consistent with the finding that *Hm* did not exhibit abnormality in digit number. Taken together, these results indicate that HIS acts as a new regulatory region that induces *Shh* expression in the interdigital region at the later stages of limb development when *Shh* expression has normally ceased in the ZPA.

BMP signaling positively regulates interdigital cell death ([@r23]). To investigate whether the ectopic *Shh* expression in *Hm* affects BMP signaling, we examined the expression level of *Msx2*, a BMP downstream target ([@r24], [@r25]). In situ hybridization showed clearly that *Msx2* was down-regulated in the *Hm* mutant ([Fig. 5 *A* and *B*](#fig05){ref-type="fig"}). This result suggested that the ectopic *Shh* expression suppresses interdigital cell death through BMP down-regulation. To uncover the molecular changes of BMP signaling in the developing *Hm* limb, we analyzed the interdigital transcriptome by microarray and found a total of 892 differentially expressed genes, including *Shh* and *Msx2* (\|log2(*Hm*/WT)\| \> 1; [Fig. 5*C*](#fig05){ref-type="fig"}). We focused on those involved in BMP signaling. In contrast to *Msx2*, *Msx1* expression level was unchanged ([Fig. 5*D*](#fig05){ref-type="fig"}). There was no marked change in expression level of the BMP and BMP receptor genes. On the other hand, among BMP antagonists, only Chordin (*Chrd*) was included in the 892 differentially expressed genes. To test the possibility that the up-regulation of *Chrd* suppresses BMP signaling in the *Hm* limb, we generated a transgenic mouse that overexpresses *Chrd* in the limb. We observed soft tissue syndactyly, similar to the *Hm* phenotype, in the transgenic mouse ([Fig. 5 *E* and *F*](#fig05){ref-type="fig"}, *n* = 3/6). This successful phenocopying of syndactyly by the ectopic expression of *Chrd* suggests that *Chrd* changes may also mediate the down-regulation of BMP signaling in the *Hm* limb.

![Down-regulation of BMP signaling in *Hm*. (*A* and *B*) Ventral view of in situ hybridization of a BMP-downstream gene, *Msx2*, in E13.5 hind limb. (*C*) Differentially expressed genes in the *Hm* interdigital region compared with the wild-type interdigital region by microarray. Yellow dots indicate *Shh*, *Chrd*, and *Msx2*. (*D*) Fold change of expression level of BMP signaling genes by microarray. (*E*) Micro-CT image of a ventral view of the right hind limb of a *Chrd*-transgenic mouse at P0. (Scale bar, 1 mm.) (*F*) Transverse section of the micro-CT image in *E*. Sectioning position is shown by the yellow dotted line in *E*.](pnas.1713339115fig05){#fig05}

Discussion {#s2}
==========

Enhancer Adoption by Genomic Insertion in *Hm*. {#s3}
-----------------------------------------------

Genetic mechanisms underlying enhancer acquisition are currently categorized into three types: de novo acquisition by accumulation of nucleotide substitutions, insertion of a TE, and acquisition by chromosomal rearrangement ([@r3]). The third type, in which a preexisiting enhancer for one gene is captured by another gene, is termed enhancer adoption ([@r26]). While de novo acquisition requires a long time for a new enhancer to emerge, the latter two mechanisms, insertion of a TE and chromosomal rearrangement, can take place rapidly and saltationally. Many cases of enhancer acquisition by TE insertion have been reported ([@r27], [@r28]). For example, retrotransposition of a short interspersed element created a new enhancer to regulate Fgf8 expression in mouse forebrain and may have contributed to the evolution of the mammalian neuronal networks ([@r29]). By contrast, there are very few reports that enhancer adoption due to chromosomal rearrangement has occurred in evolution ([@r30], [@r31]).

This study revealed that a 150-kb genomic fragment, which was derived from Chr14, was inserted into the region upstream of *Shh* in Chr5 of the *Hm* genome. As a consequence, *Shh* was ectopically expressed in the interdigital region and led to syndactyly and web formation. This syndactyly phenotype is very similar to the previously reported case of enhancer adoption by *Shh* ([@r26]). Removing HIS from Chr5 in the *Hm* genome restored normal *Shh* expression and limb morphology, which demonstrated that the insertion of HIS is the direct cause of syndactyly with webbing. Thus, this study provides direct evidence that enhancer adoption can cause morphological alteration. Our BAC-transgenic reporter assay revealed that HIS in Chr14 of wild-type mouse also has enhancer activity in the interdigital region ([Fig. 2 *H* and *I*](#fig02){ref-type="fig"}). The microarray assay detected expression of *Slitrk6*, which neighbors HIS, in the interdigital region of wild-type mouse ([Dataset S5](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1713339115/-/DCSupplemental)), implying that HIS at the original position in Chr14 has tissue-specific enhancer activity. On the other hand, *Slitrk6* KO mice show a reduction of innervation in the cochlea but no external abnormality ([@r32]). Given that removing HIS from mouse Chr14 did not cause any visible phenotype, any regulatory activity of the original HIS in Chr14 has little impact on limb development.

The result of a series of partial deletion experiments clearly showed that at least two regions in HIS are necessary for the syndactyly phenotype of *Hm* ([Fig. S2](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1713339115/-/DCSupplemental)). One of them, region 1, contains the interdigital enhancer e2 ([Fig. 2*K*](#fig02){ref-type="fig"}). On the other hand, region 2 contains two enhancers, e5 and e7, which induce reporter expression broadly in autopod and specifically in interdigits, respectively ([Fig. 2 *M*, *N*, and *P*](#fig02){ref-type="fig"}). These results imply that neither one of the three enhancers represents the total regulatory activity of HIS. Instead, it is most likely that a cooperative activity of these enhancers is necessary for the interdigital regulation of *Shh* in *Hm*. It is consistent with recent reports that many genes are regulated by multiple enhancers ([@r33][@r34]--[@r35]). Thus, in general, insertion of a large genomic fragment such as HIS can cause enhancer adoption, bringing a set of enhancers, which eventually leads to morphological change.

Recent whole-genome sequencing analyses have revealed a vast number of structural variants, a median of 18.4 Mbp per diploid genome, in human individuals. It is interesting to note that they are enriched around expression-quantitative trait loci ([@r36]). In addition, potential enhancers exist throughout the vertebrate genome ([@r37]). Taking all these findings into account, it is possible that numerous sequences in human genomes have potential enhancer activity and that enhancer adoption by chromosomal rearrangement occurs frequently in human populations. Recent reports that certain genetic diseases are caused by enhancer adoption ([@r26], [@r38]) support this assertion.

The limb enhancer MFCS1 is known to topologically interact with the *Shh* promoter beyond the long distance ([@r39]), and we found a small or negligible effect of HIS on the enhancer activity of MFCS1. This implies that frequent enhancer adoption can occur at the genome-wide scale, adding novel expression domains without disturbing original enhancer activity.

We found that the HIS inversion in Chr5 dramatically changed *Shh* expression level and resulted in a much severer morphological defect than that of the original *Hm* heterozygote. In addition to syndactyly, the inversion caused other abnormalities including increased muscle volume in the autopod and cleft palate, the latter of which is perhaps the cause of perinatal lethality. Few studies to date have documented orientation-dependent enhancer activity ([@r40], [@r41]). Recently, it was reported that orientation-dependent CTCF binding sites determine topological DNA looping for promoter--enhancer interaction and thereby exert proper gene regulation ([@r42]). We could not identify any CTCF binding sites in the original HIS in Chr14 by in silico searching of public databases. It is possible that another unknown orientation-sensitive sequence, rather than CTCF binding sites, exists in HIS.

Ectopic *Shh* Expression and Downstream Targets. {#s4}
------------------------------------------------

Ectopically expressed *Shh* in the *Hm* mutant up-regulates *Chrd* expression and down-regulates *Msx2*, a BMP signaling marker ([Fig. 5](#fig05){ref-type="fig"}). BMP signaling positively regulates interdigital cell death ([@r43], [@r44]). Since CHRD antagonizes BMP signaling ([@r45]), it is reasonable that up-regulation of *Chrd* via ectopic *Shh* expression results in inhibition of interdigital cell death. Indeed, our transgenic expression of *Chrd* clearly recapitulated syndactyly, consistent with earlier findings that ectopic expression of Gremlin (*Grem*) and Noggin (*Nog*), two other BMP antagonists, also inhibited interdigital cell death ([@r46], [@r47]). This molecular model of syndactyly in *Hm* is consistent with previous reports that ectopic expression of *Shh* suppresses interdigital cell death ([@r26], [@r48]).

Proper spatiotemporal gene regulation is essential for executing the developmental program. When the ectopic expression level of *Shh* was elevated by the inversion of HIS, digit patterning did not change. It is known that ectopic *Shh* expression in the anterior region of the early stage limb bud causes polydactyly ([@r14], [@r17]). In another mutant, Short digits (*Dsh*), ectopic *Shh* expression in the joint region causes brachydactyly with shortened digit length ([@r49]). Thus, both the timing and the pattern of ectopic expression of *Shh* are crucial for proper limb development. A change of *Shh* expression induces different downstream targets of *Shh*. In the early limb bud (approximately E9.0 to E12), in contrast to CHRD, another BMP antagonist, GREM, is induced under the control of SHH signaling ([@r50]). This sensitivity of GREM to SHH signaling disappears approximately when *Shh* expression ceases in the ZPA, which results in termination of the SHH--GREM--FGF feedback loop ([@r51]). This switching of sensitivity from early to later stages in limb development likely alters the downstream pathway of SHH signaling. In the *Hm* limb, we could not detect any difference in Fgf4 expression, suggesting that early developmental events relying on the SHH--GREM--FGF feedback loop terminated properly in the *Hm* limb.

Reduction of interdigital cell death, which leads to interdigital web formation, arose recurrently in independent lineages of different taxa. In this convergent evolution, gain of *Grem* expression was purportedly a molecular mechanism by which interdigital webbing emerged in the limbs of duck and bat ([@r46], [@r52]). We propose that gain of expression of *Chrd*, another BMP antagonist, may also have contributed to interdigital web formation in nature.

Materials and Methods {#s5}
=====================

Microarray data have been deposited in the GEO of NCBI under accession no. GSE98424 and are available in [Dataset S5](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1713339115/-/DCSupplemental). ATAC-seq data have been deposited in the DRA of DDBJ under accession no. DRA006161. An extended description of the materials and methods is provided in [*SI Materials and Methods*](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1713339115/-/DCSupplemental).

Animal experiments in this study were approved by the Animal Care and Use Committee of National Institute of Genetics (NIG).
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